Alzheimer's Disease Clinical Trials

Find Alzheimer's Disease Clinical Trials Near You

First-in-Human Evaluation of [11C]JMJ-129-d2 for PDE4D Imaging in Healthy Volunteers

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

Background: PDE4D is a protein found in the brain. It helps control chemical signals that affect mood, memory, and thinking. Problems with PDE4D may play a role in depression and Alzheimer's disease. Being able to measure PDE4D levels in the body would help doctors identify and manage these diseases. Researchers want to find out if a new tracer (a radioactive substance injected during imaging scans) can help them see PDE4D in people more effectively.

Objective: To test a new tracer (\[11C\]JMJ-129-d2) during imaging scans of the brain and body in healthy people.

Eligibility: Healthy people aged 18 years and older. They must have been screened under protocols 01M0254 or 17M0181.

Design: All participants will give samples of blood and urine. They will have a test of their heart function. A plastic tube will be inserted into a vein in their arm; the new tracer will be given through this tube. Some participants will have 1 positron emission tomography (PET)/computed tomography (CT) scan of their whole body. They will lie on a padded bed that slides into a doughnut-shaped machine; the machine uses x-rays to create images of the inside of the body. Some participants will have 1 or 2 PET/CT scans of their brain only. Their head will be supported to keep it still during the scan. They will also have a magnetic resonance imaging (MRI) scan of the brain. MRI uses magnetic fields to capture images of the inside of the body. The MRI scan may require a second visit. All participants will receive a follow-up call to check on their well-being 1 to 3 business days after their scans.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 105
Healthy Volunteers: t
View:

• EXCLUSION OF PREGNANT OR BREASTFEEDING WOMEN

• Pregnant women will be excluded because this protocol involves exposure to ionizing radiation. Lactating women will be excluded because radioisotopes may be excreted in milk. We will perform a urine pregnancy test at screening and prior to all procedures to ensure participants are not pregnant. The test must be negative in order to continue on the study. In addition to completing a negative urine pregnancy test, on the day of PET scanning prior to PET scan procedures, participants of childbearing potential will undergo a clinical pregnancy screening interview with a licensed independent practitioner to confirm lack of pregnancy.

• EXCLUSION OF PARTICIPANTS WHO ARE HIV POSITIVE

• Persons with HIV infection are excluded because HIV infection itself may change cAMP signaling.

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Tara N Turon, C.R.N.P.
tara.turon@nih.gov
(301) 827-6599
Backup
Robert B Innis, M.D.
robert.innis@nih.gov
(301) 594-1368
Time Frame
Start Date: 2026-11-02
Estimated Completion Date: 2031-02-05
Participants
Target number of participants: 40
Treatments
Other: One-arm
All subjects will receive the same tests.
Related Therapeutic Areas
Sponsors
Leads: National Institute of Mental Health (NIMH)

This content was sourced from clinicaltrials.gov